These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 31632754)

  • 21. Titration of pulmonary arterial hypertension therapeutics: Experience-based recommendations.
    Lombardi S; Kingman M; Duncan M; Berngard SC; Fernandes T
    Respir Med; 2018 Oct; 143():139-146. PubMed ID: 30261985
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pulmonary arterial hypertension: on the way to a manageable disease.
    Mucke HA
    Curr Opin Investig Drugs; 2008 Sep; 9(9):957-62. PubMed ID: 18729002
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Real-Life Experience with Selexipag as an Add-On Therapy to Oral Combination Therapy in Patients with Pulmonary Arterial or Distal Chronic Thromboembolic Pulmonary Hypertension: A Retrospective Analysis.
    Berlier C; Schwarz EI; Saxer S; Lichtblau M; Ulrich S
    Lung; 2019 Jun; 197(3):353-360. PubMed ID: 30963265
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and tolerability of transition from inhaled treprostinil to oral selexipag in pulmonary arterial hypertension: Results from the TRANSIT-1 study.
    Frost A; Janmohamed M; Fritz JS; McConnell JW; Poch D; Fortin TA; Miller CE; Chin KM; Fisher M; Eggert M; McEvoy C; Benza RL; Farber HW; Kim NH; Pfister T; Shiraga Y; McLaughlin V
    J Heart Lung Transplant; 2019 Jan; 38(1):43-50. PubMed ID: 30391194
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized, controlled trial.
    Jing ZC; Parikh K; Pulido T; Jerjes-Sanchez C; White RJ; Allen R; Torbicki A; Xu KF; Yehle D; Laliberte K; Arneson C; Rubin LJ
    Circulation; 2013 Feb; 127(5):624-33. PubMed ID: 23307827
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Perspectives on oral pulmonary hypertension therapies recently approved by the U.S. Food and Drug Administration.
    Hill NS; Badesch D; Benza RL; D'Eletto TA; Farber HW; Gomberg-Maitland M; Hassoun PM; Preston I
    Ann Am Thorac Soc; 2015 Feb; 12(2):269-73. PubMed ID: 25590376
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A focus on riociguat in the treatment of pulmonary arterial hypertension.
    Toxvig AK; Wehland M; Grimm D; Infanger M; Krüger M
    Basic Clin Pharmacol Toxicol; 2019 Sep; 125(3):202-214. PubMed ID: 31206240
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bosentan therapy for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: A systemic review and meta-analysis.
    Chen X; Zhai Z; Huang K; Xie W; Wan J; Wang C
    Clin Respir J; 2018 Jun; 12(6):2065-2074. PubMed ID: 29393580
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Changes in the Characteristics and Initial Treatments of Pulmonary Hypertension Between 2008 and 2020 in Japan.
    Tamura Y; Kumamaru H; Inami T; Matsubara H; Hirata KI; Tsujino I; Suda R; Miyata H; Nishimura S; Sigel B; Takano M; Tatsumi K;
    JACC Asia; 2022 Jun; 2(3):273-284. PubMed ID: 36338395
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel use of riociguat in infants with severe pulmonary arterial hypertension unable to wean from inhaled nitric oxide.
    Domingo LT; Ivy DD; Abman SH; Grenolds AM; MacLean JT; Breaux JA; Minford KJ; Frank BS
    Front Pediatr; 2022; 10():1014922. PubMed ID: 36533232
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension.
    Montani D; Chaumais MC; Savale L; Natali D; Price LC; Jaïs X; Humbert M; Simonneau G; Sitbon O
    Adv Ther; 2009 Sep; 26(9):813-25. PubMed ID: 19768639
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial.
    McLaughlin VV; Benza RL; Rubin LJ; Channick RN; Voswinckel R; Tapson VF; Robbins IM; Olschewski H; Rubenfire M; Seeger W
    J Am Coll Cardiol; 2010 May; 55(18):1915-22. PubMed ID: 20430262
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Advances in targeted therapy for chronic thromboembolic pulmonary hypertension.
    Zhang Y; Yu X; Jin Q; Luo Q; Zhao Z; Zhao Q; Yan L; Liu Z
    Heart Fail Rev; 2019 Nov; 24(6):949-965. PubMed ID: 31044326
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Medical therapies for chronic thromboembolic pulmonary hypertension: an evolving treatment paradigm.
    Bresser P; Pepke-Zaba J; Jaïs X; Humbert M; Hoeper MM
    Proc Am Thorac Soc; 2006 Sep; 3(7):594-600. PubMed ID: 16963540
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Switching from sildenafil to riociguat for the treatment of PAH and inoperable CTEPH: Real-life experiences.
    Andersen A; Korsholm K; Mellemkjær S; Nielsen-Kudsk JE
    Respir Med Case Rep; 2017; 22():39-43. PubMed ID: 28652963
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical and cost-effectiveness of epoprostenol, iloprost, bosentan, sitaxentan and sildenafil for pulmonary arterial hypertension within their licensed indications: a systematic review and economic evaluation.
    Chen YF; Jowett S; Barton P; Malottki K; Hyde C; Gibbs JS; Pepke-Zaba J; Fry-Smith A; Roberts J; Moore D
    Health Technol Assess; 2009 Oct; 13(49):1-320. PubMed ID: 19863849
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Riociguat for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
    Bishop BM
    Am J Health Syst Pharm; 2014 Nov; 71(21):1839-44. PubMed ID: 25320133
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safe and successful transition from oral selexipag to subcutaneous treprostinil in a patient with idiopathic pulmonary arterial hypertension treated with triple combination therapy.
    Adachi S; Nishiyama I; Yasuda K; Yoshida M; Nakano Y; Kondo T; Murohara T
    J Cardiol Cases; 2022 Jul; 26(1):42-45. PubMed ID: 35923524
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of selexipag in a teenage patient with pulmonary arterial hypertension.
    Bravo-Valenzuela NJM; Navarro F; Silva SP
    Ann Pediatr Cardiol; 2021; 14(1):75-78. PubMed ID: 33679065
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of pulmonary arterial hypertension in children.
    Gorenflo M; Ziesenitz VC
    Cardiovasc Diagn Ther; 2021 Aug; 11(4):1144-1159. PubMed ID: 34527540
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.